{"entity":{"id":"nct07612007","kind":"trial","name":"HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by Mayo Clinic, not yet recruiting.","summary":"HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization is a phase 2, randomised interventional study registered as NCT07612007 by Mayo Clinic, with a registry enrolment figure of 80 participants, started 2026-09-01 and due to reach its primary completion in 2028-08-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Darizmetinib; Embolization Therapy; Hepatectomy; Magnetic Resonance Imaging; Placebo Administration; Positron Emission Tomography. Conditions listed: Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Resectable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8. Primary outcome: Future liver remnant size (FLR). Colorectal eligibility wording from the registry: \"* REGISTRATION: Individuals with metachronous colorectal carcinoma liver metastases (CRCLM) after resection of the primary OR synchronous CRCLM with planned simultaneous resection of primary and metastatic disease\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07612007","url":"https://clinicaltrials.gov/study/NCT07612007"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07612007","phase":"2","setting":"Phase 2B Study to Determine Efficacy of HRX215, a First Generation MKK4 Inhibitor Drug, in Improving Regeneration of the Remnant Liver After Portal Vein Embolization (PVE) of Colorectal Liver Metastasis (CRLM)","sponsor":"Mayo Clinic","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07612007/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}